Abstract
Within the lipidome oxidized phospholipids (OxPL) form a class of chemically highly reactive metabolites. OxPL are acutely produced in inflamed tissue and act as endogenous, proalgesic (pain-inducing) metabolites. They excite sensory, nociceptive neurons by activating transient receptor potential ion channels, specifically TRPA1 and TRPV1. Under inflammatory conditions, OxPL-mediated receptor potentials even potentiate the action potential firing rate of nociceptors. Targeting OxPL with D-4F, an apolipoprotein A-I mimetic peptide or antibodies like E06, specifically binding oxidized headgroups of phospholipids, can be used to control acute, inflammatory pain syndromes, at least in rodents. With a focus on proalgesic specificities of OxPL, this article discusses, how targeting defined substances of the epilipidome can contribute to mechanism-based therapies against primary and secondary chronic inflammatory or possibly also neuropathic pain.
Highlights
Pain is the result of molecular and psycho-behavioural elements triggered by tissue damage [1]
This review focuses on the biology of oxidized phospholipids and summarizes recent data in preclinical rodent pain models that show how targeting the biological activity of OxPL can control pain or can even contribute to natural pain resolution
When applied rapidly and locally to cultured small-diameter neurons the prototypical OxPL compound 1-palmitoyl-2-glutaryl phosphatidylcholine (PGPC) induces calcium spikes – an effect mediated by transient receptor potential ankyrin 1 (TRPA1), but not Transient receptor potential vanilloid type 1 (TRPV1) [29]
Summary
Within the lipidome oxidized phospholipids (OxPL) form a class of chemically highly reactive metabolites. OxPL are acutely produced in inflamed tissue and act as endogenous, proalgesic (pain-inducing) metabolites. They excite sensory, nociceptive neurons by activating transient receptor potential ion channels, TRPA1 and TRPV1. OxPL-mediated receptor potentials even potentiate the action potential firing rate of nociceptors. Targeting OxPL with D-4F, an apolipoprotein A-I mimetic peptide or antibodies like E06, binding oxidized headgroups of phospholipids, can be used to control acute, inflammatory pain syndromes, at least in rodents. With a focus on proalgesic specificities of OxPL, this article discusses, how targeting defined substances of the epilipidome can contribute to mechanism-based therapies against primary and secondary chronic inflammatory or possibly neuropathic pain
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have